Health-related quality of life analysis of the LEAP-002 study of lenvatinib plus pembrolizumab versus lenvatinib as first-line treatment for advanced hepatocellular carcinoma
- DOI
- 10.1016/j.esmoop.2025.105065
- Published
- 2025-06
- Container
- ESMO Open
- Publisher
- Elsevier BV
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1016/j.esmoop.2025.105065,
title = {Health-related quality of life analysis of the LEAP-002 study of lenvatinib plus pembrolizumab versus lenvatinib as first-line treatment for advanced hepatocellular carcinoma},
author = {R.S. Finn and M. Kudo and P. Merle and T. Meyer and S. Qin and M. Ikeda and R. Xu and J. Edeline and B.-Y. Ryoo and Z. Ren and A.-L. Cheng and P.R. Galle and S. Kaneko and H. Kumada and S. Kamble and J.M. Norquist and K. Mody and A. Wang and L. Dubrovsky and J.M. Llovet},
year = {2025},
journal = {ESMO Open},
doi = {10.1016/j.esmoop.2025.105065},
url = {https://doi.org/10.1016/j.esmoop.2025.105065}
}RIS
TY - JOUR TI - Health-related quality of life analysis of the LEAP-002 study of lenvatinib plus pembrolizumab versus lenvatinib as first-line treatment for advanced hepatocellular carcinoma AU - R.S. Finn AU - M. Kudo AU - P. Merle AU - T. Meyer AU - S. Qin AU - M. Ikeda AU - R. Xu AU - J. Edeline AU - B.-Y. Ryoo AU - Z. Ren AU - A.-L. Cheng AU - P.R. Galle AU - S. Kaneko AU - H. Kumada AU - S. Kamble AU - J.M. Norquist AU - K. Mody AU - A. Wang AU - L. Dubrovsky AU - J.M. Llovet PY - 2025 JO - ESMO Open DO - 10.1016/j.esmoop.2025.105065 UR - https://doi.org/10.1016/j.esmoop.2025.105065 ER -
APA
Finn, R., Kudo, M., Merle, P., Meyer, T., Qin, S., Ikeda, M., Xu, R., Edeline, J., Ryoo, B., Ren, Z., Cheng, A., Galle, P., Kaneko, S., Kumada, H., Kamble, S., Norquist, J., Mody, K., Wang, A., Dubrovsky, L., & Llovet, J. (2025). Health-related quality of life analysis of the LEAP-002 study of lenvatinib plus pembrolizumab versus lenvatinib as first-line treatment for advanced hepatocellular carcinoma. ESMO Open. https://doi.org/10.1016/j.esmoop.2025.105065
Source records
- crossref · retrieved 2026-09-27T03:11:11.380Z